Eli Lilly makes largest investment in API manufacturing of synthetic medicines in US history

Eli Lilly and Company has significantly increased its investment in its Lebanon, Indiana manufacturing site to $9 billion, up from $3.7 billion. This expansion aims to boost the production of active pharmaceutical ingredients (API) for key medications, Zepbound (tirzepatide) and Mounjaro (tirzepatide), used in treating chronic diseases like obesity and type 2 diabetes.

Since 2020, Lilly has invested over $16 billion in new manufacturing sites across the US and Europe, including locations in North Carolina, Ireland, and Germany, and an additional $1.2 billion in updating existing facilities in Indianapolis and Wisconsin. These investments total more than $18 billion and are aimed at enhancing Lilly's manufacturing capabilities.

The expanded investment in the Lebanon site will create 200 new full-time jobs, increasing the workforce to 900 upon full operation, and generate over 5,000 construction jobs. The state of Indiana will support the project through infrastructure improvements, workforce development, and economic incentives. Additionally, a new learning and training center is planned as part of the LEAP industrial development, supported by partnerships with local educational institutions and workforce initiatives. The Lebanon site is expected to begin medicine production by late 2026, with operations scaling up through 2028.